Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT by Roth-Guepin, G. (Gabrielle) et al.
Oncotarget112972www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 68), pp: 112972-112979
Allogeneic stem cell transplantation in acute lymphoblastic 
leukemia patients older than 60 years: a survey from the acute 
leukemia working party of EBMT
Gabrielle Roth-Guepin1,*, Jonathan Canaani2,*, Annalisa Ruggeri3, Myriam 
Labopin3,4,5, Juergen Finke6, Jan J. Cornelissen7, Jeremy Delage8, Gernot Stuhler9, 
Monserrat Rovira10, Mike Potter11, Michael Stadler12, Hendrik Veelken13, Jean Yves 
Cahn14, Matthew Collin15, Yves Beguin16, Sebastian Giebel17, Arnon Nagler2,3,# and 
Mohamad Mohty3,4,5,#
 1Hematology Department, CHU Brabois, Nancy, France 
 2Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel
 3Acute Leukemia Working Party–EBMT and Department of Hematology and Cell Therapy, HÔpital Saint-Antoine, Paris, France
 4INSERM UMR 938, Paris, France
 5Université Pierre et Marie Curie, Paris, France 
 6Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
 7Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands
 8Service d’Hématologie et d’Oncologie, Hospital Lapeyronie CHU , University Montpellier, Montpellier, France 
 9Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden, Germany
10Hospital Clinic Barcelona, Institute of Hematology and Oncology, Department of Hematology, Barcelona, Spain 
11Institute of Hematology and Oncology, Department of Hematology, London, UK 
12 Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Medical School, Hannover, 
Germany 
13Department of Hematology, Leiden University Medical Center, Leiden, Netherlands 
14Department of Hematology, University Hospital, Grenoble, France
15 Newcastle University, Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Newcastle 
upon Tyne, UK
16University of Liege, Department of Hematology, CHU of Liège, Liège, Belgium
17 Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Gliwice, Poland
*Authors share co-first authorship
#Authors share co-senior authorship
Correspondence to: Arnon Nagler, email: Arnon.nagler@sheba.health.gov.il
Keywords: acute lymphoblastic leukemia; allogeneic hematopoietic cell transplantation; graft versus host disease;  
elderly; cytomegalovirus
Received: June 30, 2017    Accepted: November 05, 2017    Published: December 04, 2017
Copyright: Roth-Guepin  et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Hematopoietic stem cell transplantation (HSCT) is being increasingly explored 
as a treatment modality for older patients with acute lymphoblastic leukemia (ALL). 
Yet, concerns regarding the long term outcome of transplantation in older patients 
limit the wide spread applicability of this approach. In this analysis we set out to 
determine the outcome of ALL patients over the age of 60 who underwent reduced 
intensity HSCT. Herein, we present the experience of the acute leukemia working 
party (ALWP) of the EBMT in this age group. We analyzed a cohort of 142 patients 
transplanted in first remission with a median age of 62 (range 60–76 years) and a 
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median follow-up period of 36 months post-transplant. At 3 years, overall survival 
(OS) and leukemia-free survival were 42% and 35%, respectively. Multivariate 
analyses identified cytomegalovirus (CMV) donor-recipient matching (CMV D+/R+) 
to be significantly associated with inferior OS. Patients transplanted from unrelated 
donors experienced increased grade II-IV acute graft versus host disease compared 
to those receiving grafts from matched related donors [Hazard ratio (HR) of 3.7, 
95% confidence interval (CI), 1.75–7.8; p = 0.0005). Outcome was not impacted by 
Philadelphia chromosome status. A select subset of older ALL patients will benefit 
from extended survival and a disease free state following HSCT. 
INTRODUCTION
The introduction of reduced intensity (RIC) 
allogeneic stem cell transplantation into the mainstay 
of clinical management of older patients with acute 
lymphoblastic leukemia (ALL) more than a decade 
ago [1] represented a significant paradigm change for 
clinicians treating this challenging segment of the acute 
leukemia field. As is the case for younger ALL patients, 
an allogeneic stem cell transplant endeavors to provide 
older patients with the best possibility for disease control, 
while remaining cognizant of the overarching principals 
of therapy for this unique patient population, namely 
minimizing treatment related toxicity and mortality [1–3]. 
Whereas standard chemotherapy based approaches have 
yielded for the most part disappointing results in this 
age group with long term survival of only 6–21% [4–8], 
transplant is increasingly being used in an attempt to 
improve on these suboptimal results. Yet, the benefit of 
transplantation in this age group is not as evident as that 
seen for younger patients, for example those at the 18–39 
year age group where 5 year overall survival rates of 66% 
surpass by far the reported 22% survival rate for patients 
60–69, as published recently by the Dutch cancer registry 
[9]. Moreover, given the substantial transplant related 
mortality and morbidity reported by several groups [2, 
10–13], it remains unclear which patients derive the most 
benefit from a transplant based approach. Thus, defining 
specific patient subsets who would specifically benefit 
from transplantation is of utmost importance for patients 
and clinicians alike. Using the multicenter registry of the 
acute leukemia working party (ALWP) of the European 
Society of Blood and Marrow Transplantation (EBMT) 
we provide a current assessment of the clinical landscape 
for older ALL patients over  the age of 60 undergoing 
allogeneic stem cell transplantation after a RIC regimen. 
RESULTS 
Patient, disease and transplant characteristics
In all, 142 patients were identified and their 
baseline clinical and laboratory data are summarized in 
Table 1. The median age of patients on the cohort was 
62 (range 60–76 years) with a median follow-up period 
of 36 months (range 2–123 months). Notably, a little 
more than half of the cohort analyzed was Philadelphia 
chromosome positive. Fludarabine based regimens were 
the most frequently used approaches for conditioning prior 
to transplant whereas PB was the most commonly used 
source for stem cell grafts (135 patients; 95%). Donor 
was matched sibling for 66 patients, and 10/10 HLA 
matched unrelated donors for 76 patients. Of note, most 
Philadelphia chromosome positive patients were treated 
with tyrosine kinase inhibitors (TKI) prior to transplant 
(45 patients; 70%), and 20 patients received TKI post-
transplant indicated either for prophylaxis (7 patients), 
positive minimal residual disease (MRD) studies (5 
patients) or because of relapse (8 patients).  
Acute and chronic GVHD
The cumulative incidence of grade II-IV acute 
GVHD at 100 days was 29% (95% CI: 21%–37%) while 
the incidence of grade III-IV acute GVHD was 9% 
(95% CI: 5%–15%). As shown in the univariate analysis 
presented in Supplementary Table 1, patients transplanted 
from matched unrelated donors had significantly worse 
grade II-IV acute GVHD rates compared to patients 
transplanted from matched sibling donors (39% versus 
16%; P = 0.001). As detailed in the multivariate analysis 
shown in Table 2, patients transplanted from URD 
experienced increased grade II-IV acute GVHD compared 
to patients receiving grafts from MSD (HR =  3.7, 95% CI, 
1.75–7.8; P = 0.0005). Conversely, CMV D+/R+ status 
was also associated with a trend towards a higher rate of 
grade II-IV acute GVHD (HR = 1.79, 95% CI, 0.93–3.41; 
P = 0.07).  
RI and NRM
At 3 years the cumulative incidence of relapse was 
40% (95% CI: 32%–48%) whereas the rate of NRM at 
3 years was 23% (95% CI: 16%–30%). With univariate 
analysis (Supplementary Table 2), we observed that in 
male patients receiving grafts from female donors there 
was a trend suggesting increased relapse rates (61% versus 
36%; P = 0.072). In multivariate analysis, RI was not 
significantly affected by donor source nor by Philadelphia 
chromosome positivity (Table 2). NRM was significantly 
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affected by the CMV status in both donor and patient 
whereby D+/R+ patients experienced increased NRM 
rates (HR = 2.25, 95% CI, 1.09–4.66; P = 0.028). 
GRFS, LFS and OS
Patients in the analyzed cohort had 3 year OS and 
LFS rates of 42% and 35% respectively. The most frequent 
causes of death in the analyzed cohort were leukemia 
relapse (41 patients; 49%), infection (18 patients, 21%), 
and GVHD (14 patients, 16%). Results of a univariate 
analysis are summarized in Supplementary Table 1. In 
multivariate analysis, LFS and OS rates were significantly 
influenced by CMV D+/R+ status whereby CMV D+/R+ 
(HR = 1.62, 95% CI, 1.01–2.6; P = 0.045, and HR = 1.78, 
95% CI, 1.09–2.89; P = 0.02) conferred inferior rates for 
both clinical indices. The GRFS rate was not significantly 
impacted by any of the abovementioned factors. 
Philadelphia chromosome status did not significantly 
impact on clinical outcome (Figure 1).  
DISCUSSION
Older patients with ALL are a uniquely challenging 
patient population where clinicians are faced with the 
need to maintain a finely tuned balance between treating 
leukemia optimally while minimizing the attendant 
treatment related toxicity. In this analysis we present 
our recent experience with a large group of older ALL 
patients undergoing transplant with a curative intent. Our 
data indicate that a significant subset of patients will be 
alive and disease free at 3 years following transplant (42% 
and 35%, respectively), furthermore we show that the 
traditionally designated high risk Ph+ patients experience 
equivalent clinical outcome to Ph- patients in terms of both 
leukemia control and transplant associated toxicity.
While outcome of adult patients as a whole has 
decidedly improved over the past decade [14], selection of 
the older ALL patient most suitable for undergoing HSCT 
remains a difficult and challenging clinical decision. 
Indeed, this is reflected in a wide variation in practice, 
where for example a recent survey conducted among 
Canadian hematologists revealed that only half of them 
would recommend upfront transplant for ALL patients 
over the age of 35 [15] while on the other hand published 
data from the Netherlands indicates that 19% of patients 
between the ages of 60–69 were transplanted between 
the years 2007–2012 [9]. The justified concerns of 
transplant related morbidity and mortality in the inherently 
vulnerable population of older patients must be contrasted 
with the realization of the poor outcome associated with 
non-transplant approaches yielding a five year overall 
survival rate of only 21% for non-transplanted adults 
over the age of 55 as observed for instance in the MRC 
UKALL XII/ECOG E2993 [6, 16]. In our current analysis 
we found that older patients attained survival rates of more 
than 40%, in agreement with recently published data in 
older ALL patients [17, 18], and probably in concurrence 
also with the MRC UKALL XII/ECOG E2993 [6] and 
the Japanese experience [19] which evaluated survival at 
different time points (5 and 2 years respectively). 
Our results confirm that the transformative role 
of TKI in Ph+ ALL also extends to the segment of older 
Ph+ patients undergoing transplantation. Indeed, our 
data suggests that for older patients with Philadelphia 
chromosome positive ALL, prognosis equates with that of 
Philadelphia chromosome negative patients. Accordingly, 
it may possible to consider that in older Ph+  patients 
fit for transplant, Philadelphia chromosome status no 
longer designates patients as having higher risk disease, 
a designation which was based on the historical poor 
outcomes in this patient population [20, 21]. 
Data from our group [22] and others [13, 17, 
23] have established the non-inferiority of RIC and 
myeloablative conditioning in terms of relapse incidence. 
Yet, the optimal RIC regimen has yet to be determined. 
Most of the centers in our cohort used reduced intensity 
fludarabine based regimens with either melphalan or 
busulfan, a pattern shared with the experience reported by 
others [11, 18, 19]. Kanamori and colleagues suggested 
that fludarabine/busulfan was superior to fludarabine/
melphalan although their results did not reach statistical 
significance [19]. As of now, no data exist to demonstrate 
a definitive advantage in using a given conditioning 
regimen. Our retrospective study was not designed to 
assess the differences between the various conditioning 
regimens and thus the optimal conditioning regimen to 
use in this setting remains an open question. 
An unexpected finding in our analysis pertained to 
the clinical impact of CMV donor-recipient matching. 
We found CMV D+/R+ to be significantly associated 
with inferior overall survival and leukemia free survival 
coupled with increased non-relapse mortality.  In an earlier 
EBMT analysis from the 1990s [24] looking at a large 
cohort of acute leukemia and chronic myeloid leukemia 
patients, those patients receiving grafts from CMV-
seropositive HLA-identical sibling donors had the same 
survival as patients grafted from seronegative donors. 
Notably, in that study patients receiving unrelated donor 
grafts from CMV-seropositive donors had an improved 
5-year survival. This issue was recently readdressed with 
data showing that for patients undergoing myeloablative 
conditioning, CMV D+/R+ donor-recipient status correlated 
with improved overall survival compared with CMV 
D-/R+. This effect was absent in the reduced-intensity 
conditioning cohort of the analysis [25]. Of note no 
distinction was made in this study between ALL and 
AML. A recently published analysis from the EBMT [26] 
on 5158 ALL patients seem to be in line with our data, 
indicating that CMV seropositivity of the donor and/or the 
recipient is significantly associated with decreased 2-year 
leukemia-free survival  and overall survival, and increased 
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Table 1: Baseline characteristics of study population
Parameter N = 142
Follow up duration in m, median (range) 36 (1.8–123.4)
Age in years, median (range) 62 (60–76)
Gender, n (%)  
    Male 65 (45.7)
    Female 77 (54.2)
ALL type  
   B-ALL 126 (88.7)
   T-ALL 11 (7.7)
   Other 5 (3.5)
Philadelphia Chromosome  
    Ph negative 59 (41.5)
    Ph positive 83 (58.4)
Donor type, n (%)  
    Identical sibling 66 (46.4)
    Matched unrelated 76 (53.5)
Stem cell source, n (%)  
    Peripheral blood 135 (95)
    Bone marrow 7 (4.9)
Conditioning regimen, n (%)  
    Flu/Mel 28 (19.7)
    Flu/Bu 58 (40.8)
    Cy/Thio 1 (0.7)
    Flu/Treo 2 (1.4)
    Bu/Clo 6 (4.2)
    Cy/Flu 3 (2.1)
    Flu/Thio/BCNU 11 (7.7)
    Cy/Treo 1 (0.7)
    TBI 32 (22.5)
 Donor-recipient CMV match, n (%)  
    CMV D−/R− 33 (23.4)
    CMV D+/R− 13 (9.2)
    CMV D−/R+ 39 (27.6)
    CMV D+/R+ 56 (39.7)
    Missing 1
Karnofsky score at transplant  
    < 90 45 (33.8)
    ≥ 90 88 (66.1)
    Missing 9
HCT-CI  
    0 41 (42.7)
    1–2 25 (26)
    ≥ 3 30 (31.2)
    Missing 46
Abbreviations: CMV, cytomegalovirus; Flu/Mel, fludarabine and melphalan; Flu/Bu, fludarabine and busulfan; Cy/Thio, cyclophosphamide and thiotepa; 
TBI, total body irradiation; HCT-CI, Hematopoietic Stem Cell Transplant Comorbidity Index.
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non-relapse mortality. Why donor-recipient CMV 
matching would impact significantly on clinical outcome 
is still unclear, though some preclinical observations 
suggest that CMV infection modulates the NK cell 
repertoire following transplantation thus impacting on 
acute myeloid leukemia relapse [27]. 
Owing to the multicenter retrospective nature of 
our analysis, interpretation of our results needs to be 
undertaken cautiously. Several factors which were not 
captured by our registry, including measurable residual 
disease (MRD) data as well as depth of molecular 
remission (in Philadelphia chromosome positive patients) 
prior to transplant, would undoubtedly would have further 
informed our analysis. In addition, we acknowledge that 
the cohort analyzed was a select group of patients fit for 
transplant which may not be completely characteristic of 
the complete older ALL patient population.  
MATERIALS AND METHODS 
Study design and data collection
This is a retrospective multicenter analysis based on 
the registry data of the ALWP of the EBMT. The EBMT 
is a voluntary working group comprising more than 500 
transplant centers that are required to report all consecutive 
stem cell transplantations and follow-ups once a year. 
Audits are routinely performed to determine the accuracy 
of the data. This study was approved by the ALWP 
institutional review board. The study was conducted in 
accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines. All patients provided written 
informed consent authorizing the use of their personal 
information for research purposes. Eligibility criteria for 
this analysis included adult ALL patients over 60 years 
of age who underwent RIC HSCT in first remission 
between 2005 and 2014. Intensity of conditioning was 
determined according to published criteria [28]. Stem cell 
graft consisted of either bone marrow (BM) or G-CSF 
mobilized peripheral blood (PB). All donors were HLA-
matched according to standard criteria (locus-A, -B, 
-C, DRB1, -DQB1). Exclusion criteria were: previous 
allogeneic, cord blood or haploidentical transplantation, 
ex vivo T cell depleted stem cell graft. Comorbidity scores 
were evaluated by the modified EBMT score [29]  and the 
HCT-CI [30]. Grading of acute GVHD and chronic GVHD 
was performed using established criteria [31, 32]. 
Statistical analysis
Clinical outcomes were evaluated as follows: (i) non-
relapse mortality (NRM), defined as death without previous 
relapse; (ii) relapse incidence (RI), defined on the basis of 
morphological evidence of leukemia in bone marrow or other 
extramedullary organs; (iii) leukemia-free survival (LFS), 
defined as the time from transplantation to first event (either 
relapse or death in complete remission); (iv) GVHD-free/
relapse-free survival (GRFS), defined as events including 
grade 3–4 acute GVHD, extensive chronic GVHD, relapse, 
or death in the first post-HCT year [33]; and (v) overall 
survival. Cumulative incidence curves were used for RI and 
NRM in a competing risks setting, since death and relapse are 
competing. Probabilities of OS, LFS, and LFS were calculated 
using the Kaplan–Meier estimate. Univariate analyses were 
done using the Gray’s test for cumulative incidence functions 
and the log rank test for OS, GRFS, and LFS.  Multivariate 
analyses were performed by stepwise selection of variables 
associated with p < 0.15 in univariate analysis. All tests were 
two-sided with the type I error rate fixed at 0.05. Statistical 
analyses were performed with SPSS 19 (SPSS Inc, Chicago, 
Figure 1: Outcome of ALL patients over the age of 60 following transplantation in CR1 per Philadelphia chromosome 
status. (A)- OS, (B)- LFS.
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IL, USA) and R 2.13.2 (R Development Core Team, Vienna, 
Austria) software packages.
CONCLUSIONS 
Taken as a whole, our findings indicate that 
allogeneic stem cell transplantation is older patients with 
ALL is feasible and offers the possibility of a long term 
disease free state in some patients regardless of Philadelphia 
chromosome status. Patients in first remission, with 
matched sibling donors, and with CMV donor-recipient 
matching other than CMV D+/R+ probably fare better than 
other patients. As we expect novel therapeutics to form 
the centerpiece of management of ALL patients in the 
near future, it is cautiously anticipated and hoped that the 
outcome of older patients with ALL will further improve. 
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